A recent article reported the use of CD34 selected bone marrow for eight patients with genetic diseases. 1 The summary states that all patients engrafted and none developed GVHD. However, our clinical experience and closer analysis of the series of Gaipa et al is worthy of further comment.
Gaipa et al report the use of unrelated BM subjected to T-and B-cell depletion by the use of positive selection for CD34 using the CliniMACS device and with a T-cell add back on day 0 to provide 0.3-0.5 Â 10 6 CD3 cells/kg. However, two of the cases of mucopolysaccharidosis type 1 (MPS-1H) were second BMTs. The authors had already commented on the propensity of MPS-1 patients to reject their first BMT. After having been conditioned once, a second procedure is more likely to achieve engraftment. If one considers the six first BMT procedures, only three out of six achieved full engraftment. Furthermore, none of the three first BMTs for MPS-1 achieved full donor chimerism.
We have used partial T-cell depletion for unrelated BMT in 18 patients and four of these were first BMTs for patients with genetic diseases. Of these, 14 patients had CD34 selection with the CliniMACS device and 10 had T-cell add back on day 0 of 5 Â 10 5 CD3 cells/kg; two of whom were first unrelated BMT for genetic disease. A 6-year-old boy with Fanconi's anaemia was conditioned with CYTBI and ATG prior to BMT from a 10/10 matched unrelated donor. The infused marrow contained 5.8 Â 10 6 /kg nucleated cells and 5.2 Â 10 6 /kg CD34 cells. The T-cell add back gave a total CD3 infusion of 5.44 Â 10 5 /kg on day 0. GVHD prophylaxis post-BMT consisted of CsA. He showed early engraftment, with a rash typical of GVHD, but then became pancytopaenic and showed progressive return of recipient T cells that did not respond to a donor lymphocyte infusion of 5 Â 10 6 /kg CD3 cells from the original bone marrow donor. A 9-year-old boy with transfusion-dependent sideroblastic anaemia and noncompliance with chelation therapy had a 10/10 matched URD.
After conditioning with BuCy, thiotepa and ATG, he received 4.0 Â 10 6 /kg nucleated cells and 3.5 Â 10 6 /kg CD34 cells. The T-cell add back gave a total CD3 infusion of 5 Â 10 5 /kg on day 0. He engrafted promptly and remains fully donor at 5 months post-BMT. He has continuing problems with gut GVHD and haemorrhagic cystitis.
We agree with Gaipa et al that, in this group of patients, TCD is an acceptable method of reducing the risks of GVHD. However, where failed engraftment is a feature of the underlying disease, T-cell depletion may well add to this risk. Using the same dose of T-cell add back with the CliniMacs device, we have had no problems with nonengraftment in seven children with malignancy, and thus preceding chemotherapy exposure.
We are continuing to follow our policy of partial T cell add back, and increasing clinical data suggest that our arbitrary figure of 5 Â 10 5 CD3 cells/kg is the right order of magnitude. However, we still feel that this is likely to be associated with a significant rate of nonengraftment or rejection in the patients with a variety of nonmalignant diseases. What other options are available to us?
Increasing the dose of T cells may increase the risk of GVHD and intensifying the conditioning may increase TRM. Another strategy may be to 'cytoreduce' patients prior to BMT. Gaipa et al comment on the fact that these patients seem to tolerate a second procedure well, and it may be that all the first transplant has done is prepare the marrow for the second course of conditioning. There are less toxic and less resource-intensive ways of achieving such cytoreduction than a failed unrelated BMT and perhaps these should be explored prior to a single BMT procedure.
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